Brief: Viracta Therapeutics Announces Positive Topline Nana-Val Results From Stage 1 Of The Naval-1 Trial

Viracta Therapeutics

15/04/2024 13:12

April 15 (Reuters) - Viracta Therapeutics Inc  VIRX.O :
    * VIRACTA THERAPEUTICS ANNOUNCES POSITIVE TOPLINE NANA-VAL
RESULTS
FROM STAGE 1 OF THE NAVAL-1 TRIAL IN PATIENTS WITH RELAPSED OR
REFRACTORY EPSTEIN-BARR VIRUS-POSITIVE (EBV+) PERIPHERAL T-CELL
LYMPHOMA
    * VIRACTA: NANA-VAL DEMONSTRATED GREATER EFFICACY THAN
NANATINOSTAT MONOTHERAPY AND WAS GENERALLY WELL-TOLERATED

Source text for Eikon:  ID:nGNXjsvX3 
Further company coverage:  VIRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))